Hamburg Gives Rallying Cry For FDA Power In Her Public Farewell
This article was originally published in The Tan Sheet
Executive Summary
The outgoing commissioner gives forceful defense of the agency’s regulatory authority and warns that lowering drug approval standards would damage patients and industry.
You may also be interested in...
Hamburg Departure Hinged On Filling FDA Leadership Roster
Susan Mayne brings “new strength and focus to CFSAN and medical countermeasures expert Luciana Borio moves to chief scientist role. Hamburg offers previews on leadership approaches of Stephen Ostroff and Robert Califf.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.